Inno-206
Recurrent Ph-Like Acute Lymphoblastic Leukemia
M.D. Anderson Cancer CenterPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Recurrent Ph-Like Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide City of Hope Medical Center | Phase 2 | B |
Cytosin-Arabinosid City of Hope Medical Center | Phase 2 | B |
PREDNISONE TABLETS City of Hope Medical Center | Phase 2 | B |
MERCAPTOPURINE ANHYDROUS City of Hope Medical Center | Phase 2 | B |
METHOTREXATE City of Hope Medical Center | Phase 2 | B |
View all 16 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →